Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA ...Middle East

HONG KONG, Jan. 26, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the New Drug Application (NDA) of its internally-developed IL-17-targeting monoclonal antibody gumokimab (AK111) has been accepted by the Center for Drug Evaluation (CDE)...

Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso's Gumokimab Monoclonal Antibody (IL-17) New Drug Application for the Treatment of Moderate to Severe Psoriasis Accepted by NMPA )

Also on site :

• Anne Burrell's Husband Looks Somber in First Photo Since Food Network Star's Death
• Iran threatens US bases in Middle East, asserts nuclear facilities undamaged
• Las negociaciones “no tienen sentido” a menos que Israel detenga los ataques, dice un portavoz del Gobierno iraní a CNN